Australia's most trusted
source of pharma news
Thursday, 21 November 2024
Posted 18 November 2024 AM
It has taken the TGA less than nine months to approve MSD's next pegged blockbuster Winrevair.
The subcutaneous treatment for pulmonary arterial hypertension (PAH) is expected to make MSD one of the biggest players in the cardiovascular market and ease the pain from Keytruda's upcoming patent expiration.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.